Posted by Michael Wonder on 21 Feb 2022
PBS arrangements for medicines for the treatment of paroxysmal nocturnal haemoglobinuria
21 February 2022 - Commencing 1 March 2022, Soliris (eculizumab) and Ultomiris (ravulizumab) will be listed on the Pharmaceutical Benefits Scheme Section 100 Highly Specialised Drugs Program for the treatment of paroxysmal nocturnal haemoglobinuria under certain conditions.
Further, access to Soliris under the Life Saving Drugs Program will be ceased for new patients from 1 March 2022, with transition arrangements in place to facilitate access to these medicines via the PBS.
